estramustine and Rectal-Neoplasms

Thirty-five patients with advanced cancers were treated with estramustine phosphate tablets (Estracyt). Doses ranged between 420 mg and 700 mg daily. One partial response was documented in a hormone resistant prostatic cancer patient. Four minor responses (less than 50% responses, or less than one month more than 50% response) were obtained; one in a hormone resistant prostatic cancer, two in metastatic colorectal cancers; and another in a malignant melanoma. Toxicity phenomena included nausea (9/35 - 25%), water retention (4/35 - 11.5%) and mild elevation of alkaline phosphatase (2/35 - 6%). Other toxicity effects were vaginal bleeding in two women, acne in one woman and mild pruritus in another patient. Myelosuppression and immune suppression were not significantly detected.

Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Drug Resistance; Estramustine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prostatic Neoplasms; Rectal Neoplasms